Anavex Life Sciences Corp.
Simbolis: AVXL
NASDAQ
3.85
USDRinkos kaina šiandien
-7.3224
P/E santykis
-2.2699
PEG koeficientas
311.23M
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Anavex Life Sciences Corp. (AVXL) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 603.07 | 151 | 149.2 | 152.1 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 13.16 | 2.7 | 3.2 | 9.1 | ||||||||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 3.22 | 0.7 | 0.4 | 0.4 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 619.45 | 154.4 | 152.7 | 161.6 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 3.36 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 3.36 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.other-assets | 8713.08 | 3.4 | 3546.7 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 619.45 | 154.4 | 152.7 | 161.6 | ||||||||||||||||||||
balance-sheet.row.account-payables | 19.05 | 4.3 | 3.8 | 4.7 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | ||||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 27.39 | 7.3 | 5.9 | 5.6 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 12823.08 | 7.3 | 4.3 | 5.6 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | -12823.08 | -7.3 | -4.3 | -5.6 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-liab | 50.11 | 12.5 | 10.2 | 10.8 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.common-stock | 0.33 | 0.1 | 0.1 | 0.1 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | -1149.33 | -293.1 | -245.6 | -197.6 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1718.35 | 434.8 | 388 | 348.3 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 569.35 | 141.9 | 142.5 | 150.8 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 619.45 | 154.4 | 152.7 | 161.6 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-equity | 569.35 | 141.9 | 142.5 | 150.8 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 619.45 | - | - | - | ||||||||||||||||||||
Total Investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-debt | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.net-debt | -603.07 | -151 | -149.2 | -152.1 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -43.16 | -47.5 | -48 | -37.9 | ||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.stock-based-compensation | 13.31 | 16.4 | 18.4 | 8.2 | ||||||||||||||||||||
cash-flows.row.change-in-working-capital | -0.31 | 2.5 | 5.4 | -0.7 | ||||||||||||||||||||
cash-flows.row.account-receivables | 0.55 | 0.5 | 5.9 | -4.3 | ||||||||||||||||||||
cash-flows.row.inventory | -1.53 | -0.5 | -5.9 | 4.3 | ||||||||||||||||||||
cash-flows.row.account-payables | -1 | 0.5 | -0.9 | 0.8 | ||||||||||||||||||||
cash-flows.row.other-working-capital | 1.67 | 2 | 6.3 | -1.5 | ||||||||||||||||||||
cash-flows.row.other-non-cash-items | 0.84 | 0.8 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -29.31 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.common-stock-issued | 27.93 | 27.9 | 21 | 153.2 | ||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.other-financing-activites | 1.52 | 1.8 | 0.3 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 29.45 | 29.7 | 21.3 | 153.2 | ||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-change-in-cash | 0.14 | 1.9 | -2.9 | 122.9 | ||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 603.07 | 151 | 149.2 | 152.1 | ||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 602.93 | 149.2 | 152.1 | 29.2 | ||||||||||||||||||||
cash-flows.row.operating-cash-flow | -29.31 | -27.8 | -24.2 | -30.4 | ||||||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.free-cash-flow | -29.31 | -27.8 | -24.2 | -30.4 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 40.33 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 11.33 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | 2.58 | 2.7 | 3.3 | -0.1 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 51.67 | 55.8 | 51 | 41.9 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 51.67 | 55.8 | 51 | 41.9 | ||||||||||||||||||||
income-statement-row.row.interest-income | 7.26 | 6.5 | 0.9 | 0 | ||||||||||||||||||||
income-statement-row.row.interest-expense | -1.13 | 1 | 0.9 | 0 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 2.83 | 2.7 | 6.8 | 4.3 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 2.58 | 2.7 | 3.3 | -0.1 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 2.83 | 2.7 | 6.8 | 4.3 | ||||||||||||||||||||
income-statement-row.row.interest-expense | -1.13 | 1 | 0.9 | 0 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 2.23 | 0 | 4.3 | 0.2 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | -46.68 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | -48.91 | -47.5 | -54.4 | -41.9 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | -43.04 | -47.5 | -47.6 | -37.6 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 0.11 | 0 | 0.4 | 0.3 | ||||||||||||||||||||
income-statement-row.row.net-income | -43.16 | -47.5 | -48 | -37.9 |
Dažnai užduodami klausimai
Kas yra Anavex Life Sciences Corp. (AVXL) bendras turtas?
Anavex Life Sciences Corp. (AVXL) bendras turtas yra 154386000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra N/A.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.000.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra -0.357.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.000.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.000.
Kas yra Anavex Life Sciences Corp. (AVXL) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -47491000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 0.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 55756000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 143765000.000.